IDEAYA Begins Clinical Testing of IDE892 for MTAP-Deleted Cancers

IDEAYA Biosciences has enrolled the first patient in a Phase 1/2 trial testing IDE892, a novel PRMT5 inhibitor, in combination with its MAT2A-targeting drug IDE397. The study focuses on non-small cell lung cancer and pancreatic cancer, where MTAP-deletion creates specific vulnerabilities that researchers aim to exploit for deeper tumor responses.

Today, 13:13· Money Talk· 1,085 reads

IDEAYA Begins Clinical Testing of IDE892 for MTAP-Deleted Cancers

The clinical trial follows preclinical success where the dual inhibition of PRMT5 and MAT2A yielded durable anti-tumor activity at doses lower than those required for monotherapy. IDE892, which IDEAYA describes as a best-in-class agent, features a 1,400-fold selectivity for MTA-PRMT5 cooperative binding over SAM-PRMT5, an attribute designed to broaden the therapeutic window. The company is also investigating the drug's potential as a partner for pan-RAS inhibitors, including a collaboration with Roche using the agent RG6505.

MTAP-deleted tumors represent a significant clinical challenge, occurring in up to 40% of pancreatic cancers and roughly 15% of non-small cell lung cancer cases. Currently, no approved therapies exist for these specific genetic profiles. Beyond the ongoing combination trials, IDEAYA is preparing to advance a program targeting CDKN2A, a frequent co-alteration in MTAP-deficient tumors, with plans to file an investigational new drug application in the first half of 2027.

IDEAYA Begins Clinical Testing of IDE892 for MTAP-Deleted Cancers

Comments (0)